Literature DB >> 3281702

Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine.

H Y al-Idrissi1, E M Ibrahim, K A Abdullah, W A Ababtain, H A Boukhary, H M Macaulay.   

Abstract

A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of high-dose dexamethasone (Protocol D) with a combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD) in the management of chemotherapy-induced nausea and vomiting in cancer patients. All entered patients had received no prior chemotherapy. During the study chemotherapy was administered on an inpatient basis. The majority of patients (94%) were treated with cytotoxic drugs of significant emetogenic activity and 40% of the study group received cis-platin-containing combinations. Of the 60 evaluable patients, complete antinausea and antivomiting effects of D were observed in 30 (50%) and 34 (57%), respectively and of DMD in 17 (28%) and 26 patients (43%) respectively. The difference was not statistically significant (P = 0.09 and 0.24, respectively). Lack of significant difference between the two regimens was demonstrated irrespective of the administered cytotoxic drugs. The DMD protocol caused more adverse reactions than D. While 27 patients (45%) experienced no side effects from D, only 14 (24%) remained free of complications due to DMD (P = 0.001). Furthermore, DMD produced more sedation, insomnia, headache, diaphoresis, dizziness and diarrhoea than the D regimen. In addition it gave rise to more adverse effects on appetite and activity. Upon direct questioning, 37 patients (62%) expressed a preference for D, 14 (23%) preferred DMD and 9 (15%) found no difference between the two regimens. We conclude that, while the short DMD protocol has an antiemetic activity equivalent in its effectiveness to D, its associated adverse reactions would minimize its usefulness. Therefore, further investigations should be conducted to find a safer and more potent combination of antiemetics suitable for therapy in an outpatient setting.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281702      PMCID: PMC2246525          DOI: 10.1038/bjc.1988.68

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS.

Authors:  C G MOERTEL; R J REITEMEIER; R P GAGE
Journal:  JAMA       Date:  1963-10-12       Impact factor: 56.272

2.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

Authors:  C Morran; D C Smith; D A Anderson; C S McArdle
Journal:  Br Med J       Date:  1979-05-19

3.  Controlled clinical studies of orally administered antiemetic drugs.

Authors:  C G Moertel; R J Reitemeier
Journal:  Gastroenterology       Date:  1969-09       Impact factor: 22.682

4.  Antiemetics: neurotransmitter receptor binding predicts therapeutic actions.

Authors:  S J Peroutka; S H Snyder
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

5.  Effective control of cisplatin-induced nausea using high-dose steroids and droperidol.

Authors:  B A Mason; J Dambra; B Grossman; R B Catalano
Journal:  Cancer Treat Rep       Date:  1982-02

6.  Emesis as a critical problem in chemotherapy.

Authors:  J Laszlo; V S Lucas
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

7.  Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.

Authors:  S B Strum; J E McDermed; R W Opfell; L P Riech
Journal:  JAMA       Date:  1982-05-21       Impact factor: 56.272

8.  Nausea and vomiting as major complications of cancer chemotherapy.

Authors:  J Laszlo
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

Review 9.  The control of chemotherapy-induced emesis.

Authors:  L J Seigel; D L Longo
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

10.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.